Nonsignificant difference btw IFX, VDZ and USTK in mod-severe UC #colitis p failure of conventional therapy in very small study from 🇯🇵. Only predictor for IFX arm: combo therapy #DDW2025 #IBD

Afimkibart (TL1-A inhibitor) demonstrated efficacy for objective EP in moderate-severe UC #colitis in phase 2b clinical trial w no dose response, presented by Dr Vipul Jairath MBChB DPhil. The competition in this MOA class is intensifying #DDW2025 #IBD

Anti-TL1-a 3.0! Duvakitug demonstrated efficacy primarily for endoscopic endpoints in mod-severe #crohnsdisease in a first of its kind in #IBD basket trial (parallel UC, CD). Well tolerated Vipul Jairath MBChB DPhil #DDW2025 #IBD

2nd line VDZ (slightly) superior to IFX in UC #colitis patients after failure of ADA or GOL in H2H RCT; efficacy @ week 14 for CSF remission, endo response and remission. This can be practice-changing, pending wk 54 data #DrGuillaumeBouguen #DDW2025 #IBD

First dedicated open label trial of steroid-free induction with TOFA in ADT-naive moderate-severe UC #colitis showing effectiveness similar to steroids but superior safety - #DrShankarRoy. U.S. FDA are you listening? #DDW2025 #IBD

Second prospective randomized trial in ASUC #colitis showing lack of significant benefit for dose intensified IFX (dashboard-driven vs. SOC). Lower colectomy rate in the intensified dosing Gecse Krisztina #DDW2025 #IBD

Randomized trial showing non-inferiority of HDWLE vs. chromoendoscopy (dye-spraying) for neoplasia detection in #IBD. Per lesion diff significant in favor of DSCE w 10x fewer biopsies❗️0/700 non-targeted biopsies positive for dysplasia Mohammed El-Dallal #DDW2025 #IBD

FOMO #DDW2025 Digestive Disease Week? You still have time to register for our annual Swedish #IBD update! We will be the first meeting on the West coast to bring you up to speed with the most relevant topics and trials presented at #DDW2025. Sign up here 👇seattleibd.org

This 👇 is HUGE. Not just superior but also by how much

Only 2 weeks left until the Swedish #IBD Updates conference: star faculty including the one and only Stephen B. Hanauer, MD giving the keynote lecture; hot topics on the agenda like "the battle of the p19's", positioning therapies for UC, ASUC; join us 👇seattleibd.org

A few spots left (for in person) this Saturday! The Swedish Annual #IBD update! For Pacific NW-ers, your best chance to hear #DDW2025 updates, #AI in GI and IBD, positioning therapies in UC, management of #crohnsdisease complications, IBD-hepatology, etc. seattleibd.org

Weather blues 💙 tomorrow? No worries, join us for a fun, educational event to learn about what is hot and what is not in #IBD. Register below 👇 seattleibd.org

The great Stephen B. Hanauer, MD giving the keynote presentation on precision medicine in IBD at the Swedish #IBD updates 2025 Swedish Gastroenterology #seattleIBD

#IBD is a spectrum of conditions with similar pathogenesis but different expressions dependent on a convergence of factors including genetics and the environment Stephen B. Hanauer, MD #seattleibd

Why and when to consider #IBD treatment de-escalation by #DrNinaSaxena #seattleIBD

Helpful steps to integrate treat-to-target T2T in the #IBD clinical practice by #DrLuluIlesShih Swedish Gastroenterology #seattleIBD